These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Qu X, Huang X, Yan W, Wu L, Dai K. Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739 [Abstract] [Full Text] [Related]
5. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E. J Nucl Med; 2004 Feb; 45(2):272-8. PubMed ID: 14960647 [Abstract] [Full Text] [Related]
7. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, Catalano L, Liuzzi R, Rotoli B, Del Vecchio S, Pace L, Salvatore M. J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607 [Abstract] [Full Text] [Related]
8. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18. Basu D, Siegel BA, McDonald DJ, Nussenbaum B. Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):801-5. PubMed ID: 17709620 [Abstract] [Full Text] [Related]
9. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI. Seemann MD, Meisetschlaeger G, Gaa J, Rummeny EJ. Eur J Med Res; 2006 Feb 21; 11(2):58-65. PubMed ID: 16504962 [Abstract] [Full Text] [Related]
10. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Roh JL, Yeo NK, Kim JS, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY. Oral Oncol; 2007 Oct 21; 43(9):887-93. PubMed ID: 17207656 [Abstract] [Full Text] [Related]
11. 18F-FDG PET/CT for staging of penile cancer. Scher B, Seitz M, Reiser M, Hungerhuber E, Hahn K, Tiling R, Herzog P, Reiser M, Schneede P, Dresel S. J Nucl Med; 2005 Sep 21; 46(9):1460-5. PubMed ID: 16157528 [Abstract] [Full Text] [Related]
13. [Detection of bone metastasis of prostate cancer - comparison of whole-body MRI and bone scintigraphy]. Ketelsen D, Röthke M, Aschoff P, Merseburger AS, Lichy MP, Reimold M, Claussen CD, Schlemmer HP. Rofo; 2008 Aug 21; 180(8):746-52. PubMed ID: 18512192 [Abstract] [Full Text] [Related]
15. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Castellucci P, Perrone AM, Picchio M, Ghi T, Farsad M, Nanni C, Messa C, Meriggiola MC, Pelusi G, Al-Nahhas A, Rubello D, Fazio F, Fanti S. Nucl Med Commun; 2007 Aug 21; 28(8):589-95. PubMed ID: 17625380 [Abstract] [Full Text] [Related]
16. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, Bisi G. Q J Nucl Med Mol Imaging; 2006 Mar 21; 50(1):15-22. PubMed ID: 16557200 [Abstract] [Full Text] [Related]
17. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection. Quaia E, Tona G, Gelain F, Lubin E, Pizzolato R, Boscolo E, Bussoli L. Acta Radiol; 2008 Nov 21; 49(9):995-1004. PubMed ID: 18651256 [Abstract] [Full Text] [Related]
18. Utility of 18F-fluorodeoxyglucose positron emission tomography in the preoperative staging of squamous cell carcinoma of the oropharynx. Kim MR, Roh JL, Kim JS, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY. Eur J Surg Oncol; 2007 Jun 21; 33(5):633-8. PubMed ID: 17391904 [Abstract] [Full Text] [Related]